Study of Efficacy and Safety of Investigational Treatment in Patients With Hidradenitis Suppurativa

Inclusion Criteria: * Diagnosis of HS or signs and symptoms consistent with HS for at least 3 months before screening in the judgment of the investigator. * Stable disease for at least 2 months before screening in the judgment of the investigator. * A woman of childbearing potential must use appropriate contraceptive measures during the study period. * A woman of childbearing potential must have a negative urine pregnancy test result at screening. * Written informed consent must be obtained before any study procedure is performed. Exclusion Criteria: * Pregnant or breastfeeding. * Any active skin disease that may interfere with evaluation of study drug or outcome assessment. * History or evidence of a clinically significant disorder, condition, or disease that would pose a risk to participant safety or interfere with the study evaluation, procedures, or completion in the judgment of the investigator. * Change in smoking or marijuana history within 3 months before Day 1 or planned during study period.